------------------------------------------------------------
[link removed]


** Charting the Future of HIV Prevention and Global Health Advocacy and Action
------------------------------------------------------------
December 22, 2021

Dear Advocate,

We close the year with the exciting news that injectable cabotegravir has gained FDA approval as PrEP. ([link removed]) It’s an important achievement, adding another much needed HIV prevention option to the mix. But as we reflect on the many lessons of the year, we recognize this milestone sits within a larger, more complicated context. ([link removed]) This regulatory approval is only one, albeit essential, step in a greater effort to transform options into real choices that have impact on epidemics and in people’s lives.

The story of 2021 is one of advances, disappointments, uncertainty, perseverance and solidarity. Through it all, we recognize themes that have been similar throughout AVAC’s 26-year history: follow the science, center community in the response, and lead with equity, always.

2021 brought no end to challenges in global health, and we hope that everyone finds time to reflect, and, hopefully, rejuvenate for the year ahead and the work that we hope to do collaboratively.

To start the new year right, please mark your calendars for Thursday, January 13 at 9:00 am EST for a webinar to discuss the latest ups and downs in HIV prevention, and set an advocacy agenda for the future: Ups & Downs in the Field: Setting an Agenda Together for HIV Prevention in 2022; click here to register ([link removed]) .

[link removed]
In the meantime, if you’re looking to catch-up on the year that was, planning for the year ahead, or just want to have some good holiday reading and listening, here are a few important reminders of 2021:

1. On the heels of this week’s FDA approval ([link removed]) of injectable PrEP, and with decisions from other regulatory bodies anticipated in early 2022 ([link removed]) , check out An Advocates’ Primer on Injectable Cabotegravir for PrEP ([link removed]) and explore our Biomedical Prevention Implementation Collaborative (BioPIC) ([link removed]) that is working to close the gap between research, regulatory approval and rollout for injectable cabotegravir and future products.
2. In January, WHO officially recommended the Dapivirine Vaginal Ring (DVR) be included as a prevention choice for women at risk of HIV ([link removed]) . The regulatory approval process has taken longer ([link removed]) than we all wanted with various twists and turns, but happily WHO just this month restated their commitment ([link removed]) to support countries as they consider whether to include the DVR as an additional prevention option for women.
3. With the introduction of the new ring and injectable PrEP on the horizon in 2022, it has never been more important to reflect on the lessons we recently documented from the past decade of oral PrEP and their implications for these next generation PrEP products ([link removed]) .
4. Even as the new PrEP options rollout, the need to develop additional PrEP options continues. We have a full menu of resources related to the research agenda. New ethics guidelines support ongoing and future trials in an era of existing PrEP, which we reviewed earlier this year ([link removed]) ; our Px Pulse ([link removed]) podcast ([link removed]) series Research Fundamentals looks at the fundamental role of endpoints ([link removed]) in trial design; our continued focus on next generation trial design ([link removed]) includes this quick reference to critical updates on ethical guidance in
HIV prevention trials ([link removed]) ; and a new fact sheet on Evolving Designs for HIV Prevention Trials ([link removed]) that includes descriptions of new trials of the six-monthly injectable lenacapavir and once-monthly oral islatravir. Unfortunately, news in the past two weeks about holds on both the lenacapavir ([link removed]) and islatravir ([link removed]) trials (for very different reasons) are important reminders of the uncertainties of product development AND the enduring need for research literacy, ongoing stakeholder engagement and Good Participatory Practices ([link removed]) to help navigate it all.
5. Beyond ARV-based PrEP, what’s the future of antibody mediated prevention, following important results that were presented in January? Read our Understanding Results of the AMP Trials ([link removed]) , and listen to our Px Pulse ([link removed]) podcast ([link removed]) with a Dive into the AMP Trials ([link removed]) .
6. Nothing about HIV vaccine research has ever been easy, and results of the Imbokodo study reminded us all both how difficult this research is and how essential it continues to be. Listen to our webinar ([link removed]) from September to understand the results and their implications, and be sure to check out this special supplement on HIV vaccine R&D ([link removed]) in ([link removed]) the Journal of the International AIDS Society, including a number of c ([link removed]) ritical articles from AVAC staff and partners ([link removed]) . And if you want to learn even more about how HIV vaccine research paved the way for COVID mRNA vaccines—and how HIV might get paid back—be sure to watch this CNBC video
([link removed]) with a number of leading researchers and advocates, including our Executive Director.
7. Speaking of COVID-19, AVAC and many partners have spent the past two years developing the COVID Advocates Advisory Board (the CAAB), which is playing a critical role in engaging and convening essential conversations in responding to yet another pandemic. Check out the CAAB’s new website ([link removed]) , and listen to a webinar on the global readiness for vaccine manufacturing ([link removed]) with New York Times reporter Stephanie Nolen and another remarkable conversation on the Omicron ([link removed]) variant with CAPRISA’s Slim Abdool Karim.
8. In HIV or COVID or any area of public health, representation matters. It’s core to effective advocacy, and one of the reasons we are so excited about No Data, No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities ([link removed]) . Developed in collaboration with trans and gender diverse activists from Cape Town to Berlin, this report takes critical steps toward a comprehensive research agenda for HIV prevention that serves trans and gender diverse people.
9. Leadership also matters, which is why we are grateful to Acting US Global AIDS Coordinator Angeli Achrekar for her continued efforts to advance PEPFAR and excited about the nomination of John Nkengasong to lead PEPFAR ([link removed]) going forward. Read more about our views here ([link removed]) and here ([link removed]) .
10. Last but not least, 2021 got us at AVAC thinking not only about the larger field but our place in it. We undertook the most encompassing reflections on our work since AVAC was founded 26 years ago. As part of this process we reviewed our work from top to bottom and undertook a months-long process to forge a strategy for the years ahead that will advance HIV prevention in the broadest context necessary to advocate for global health equity. We are proud to share with you our strategic plan through 2026 ([link removed]) and our commitment to equity, diversity and inclusion ([link removed]) . We also issued a preview of our 2 ([link removed]) 021 AVAC Report: ([link removed]) Developing Options, Delivering Choices
([link removed]) , which describes the concerted actions needed to transform prevention “options”, developed through research, into prevention “choices” that reach the people who need them most.


What a year—and what a “to do” list for our ongoing collaborations with all of you! We look forward to working with you to understand how the field is evolving, where it’s stuck, and what we will do together to advance HIV prevention and drive global health equity forward—so please do ([link removed]) register to ([link removed]) join us ([link removed]) on Thursday, January 13 at 9:00 am EST to discuss the latest ups and downs and set an advocacy agenda together for the future.

In the meantime, all the best for a restful and rejuvenating holiday,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])